CLINICAL TRIALS PROFILE FOR RITUXIMAB

Biosimilar Clinical Trials for Rituximab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01459887 ↗	Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Completed	Shanghai CP Guojian Pharmaceutical Co., Ltd.	Phase 3	2006-09-01	CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases. This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP chemotherapy regimen compared with CHOP chemotherapy alone.
NCT01459887 ↗	Study of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody to Treat Non-hodgkin's Lymphoma	Completed	Shanghai CP Guojian Pharmaceutical Co.,Ltd.	Phase 3	2006-09-01	CD20, the protein which is expressed on the surface of all mature B cells, is active in many B-cell lymphomas that express this molecule such as Diffuse Large B Cell Lymphoma (DLBCL), the most frequently occurring subtype of non-Hodgkin lymphomas. In clinical practice, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone combination chemotherapy (CHOP) is still considered one of the standard treatment to DLBCL. CMAB304(Retuxira), the chimeric monoclonal antibody is designed to targeted against CD20 for treatment of lymphoma diseases. This trial aimed to observe the safety and efficacy of CMAB304, by added CMAB304 to CHOP chemotherapy regimen compared with CHOP chemotherapy alone.
NCT01759030 ↗	Study of Safety and Efficacy of BCD-020 Comparing to MabThera in Patients With Rheumatoid Arthritis	Completed	Biocad	Phase 3	2012-12-01	The purpose of this study is to prove that efficacy, safety and immunogenicity of BCD-020 is equivalent to MabThera when used in combination with methotrexate for the treatment of patient with rheumatoid arthritis

All Clinical Trials for Rituximab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001337 ↗	Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	1993-05-08	5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX, NSC-26271; Doxorubicin, DOX, NSC-123127; with Granulocyte Colony-Stimulating Factor (Amgen), G-CSF, NSC-614629....
NCT00001379 ↗	Treatment and Natural History Study of Lymphomatoid Granulomatosis	Recruiting	National Cancer Institute (NCI)	Phase 2	1995-08-07	This study will evaluate the response and long-term effects of alpha-interferon in patients with lymphomatoid granulomatosis (LYG). The disease causes proliferation of destructive cells involving the lungs, skin, kidneys, and central nervous system. Patients ages 12 and older who have LYG and who are not pregnant or breast feeding may be eligible for this study. Alpha interferon or chemotherapy, or both, will be used. Alpha interferon is a protein the body naturally produces. If patients have grade 3 disease, they will usually receive EPOCH-rituximab (EPOCH-R) chemotherapy (each letter representing a drug). If patients have grade 1 or 2 disease, the will usually receive alpha interferon. If patients have LYG after receiving alpha interferon and/or EPOCH-R, they may receive rituximab alone or with alpha interferon. Rituximab is an antibody, binding to a specific molecule (CD20) present on most B-cell lymphomas. Doses of several drugs in EPOCH-R may be increased if patients tolerated them in the previous cycle. If patients respond to EPOCH-R but still have low grade LYG, they may receive alpha interferon. Researchers will also try to obtain a biopsy of patients lesions, to help in understanding the disease. Patients self-administer alpha interferon by injection under the skin three times weekly. They will visit the clinic every 2 to 12 weeks for follow-up. Patients will receive alpha interferon for 1 year after LYG goes away, depending on response. EPOCH-R has these drugs: rituximab by vein on Day 1; prednisone by mouth on Days 1 to 5; etoposide, doxorubicin, and vincristine as a continuous intravenous infusion on Days 1 to 5; and cyclophosphamide by intravenous injection over 1 hour on Day 5. Each cycle lasts 3 weeks: 5 days of chemotherapy and 16 days of no chemotherapy. Etoposide, doxorubicin, and vincristine are infused through a small pump worn by patients. The drugs are given over 5 days through a central intravenous catheter. There are two cycles of EPOCH-R beyond a maximum response, with six cycles minimum. To reduce harm to bone marrow, patients receive granulocyte colony stimulating factor (G-CSF), self-administered by injection under the skin daily for approximately 10 days between chemotherapy cycles. If at the end of therapy, patients have a complete response, treatment will stop. If there is residual low grade disease, patients may receive alpha interferon. Alpha interferon can have flu-like side effects of headache, fever, chills, and body aches. EPOCH-R drugs can cause gastrointestinal problems, hair loss, and weakness. G-CSF can cause bone pain, body aches, and hair thinning. Chemotherapy can cause some patients to develop leukemia. This study may or may not have a direct benefit for participants. It is not certain whether the new therapy will help decrease tumors. However, knowledge gained may improve the understanding of and treatment for LYG.
NCT00001563 ↗	EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1997-01-08	The prognosis of AIDS-related Non-Hodgkin's lymphoma is poor, especially in the relapsed setting. There is no standard treatment, and the few small studies that have been conducted have reported dismal outcomes. The purpose of this study is to pilot the use of EPOCH plus rituximab in previously treated AIDS-related lymphoma. Clinical endpoints of the study include toxicity and response. Progression-free and overall survival will be measured. Tumors will be evaluated for p53 mutations, p-16, bcl-2 expression, tumor proliferation, c-myc and EBV when possible....

Clinical Trial Conditions for Rituximab

Condition Name

Condition Name for Rituximab
Intervention	Trials
Lymphoma	286
Diffuse Large B-Cell Lymphoma	140
Chronic Lymphocytic Leukemia	134

Condition MeSH

Condition MeSH for Rituximab
Intervention	Trials
Lymphoma	1283
Lymphoma, B-Cell	543
Lymphoma, Non-Hodgkin	477

Clinical Trial Locations for Rituximab

Trials by Country

Trials by Country for Rituximab
Location	Trials
Italy	772
China	716
Hungary	92
Denmark	87
Russian Federation	84

Trials by US State

Trials by US State for Rituximab
Location	Trials
Texas	389
California	387
New York	370
Ohio	254
Illinois	243

Clinical Trial Progress for Rituximab

Clinical Trial Phase

Clinical Trial Phase for Rituximab
Clinical Trial Phase	Trials
PHASE4	10
PHASE3	41
PHASE2	133

Clinical Trial Status

Clinical Trial Status for Rituximab
Clinical Trial Phase	Trials
Completed	909
Recruiting	570
Terminated	226

Clinical Trial Sponsors for Rituximab

Sponsor Name

Sponsor Name for Rituximab
Sponsor	Trials
National Cancer Institute (NCI)	326
Hoffmann-La Roche	158
M.D. Anderson Cancer Center	143

Sponsor Type

Sponsor Type for Rituximab
Sponsor	Trials
Other	2845
Industry	1395
NIH	391

Rituximab Clinical Trials Update, Market Analysis, and Forecast: Patents, Biosimilar Risk, and Revenue Exposure (Global)

Last updated: July 25, 2026

Rituximab is a foundational anti-CD20 monoclonal antibody with widespread use across NHL (including DLBCL and FL), CLL/SLL, and autoimmune indications. Commercial risk is primarily driven by biosimilar adoption across major markets rather than new-originator patent barriers, because most high-value exclusivity windows have matured and clinical development has shifted toward biosimilars, combination strategies, subpopulations, and new dosing regimens.

---

How is rituximab performing in the market today and what is the forecast by indication?

Short answer: Rituximab remains a high-volume biologic with slower category growth than branded peak years due to biosimilar substitution. The largest revenue pools are traditionally NHL and CLL; forward-looking growth depends on (1) share capture by biosimilars, (2) continued guideline use in combination regimens, and (3) steady penetration in emerging lines where rituximab remains standard of care.

Category demand drivers

• NHL guideline breadth: Rituximab is embedded in first-line and relapse regimens across DLBCL and follicular lymphoma (FL).
• CLL standard-of-care: Rituximab remains core therapy in chemoimmunotherapy and time-limited regimens in many settings.
• Autoimmune reach: Rheumatoid arthritis and other autoimmune indications remain material in some geographies, though switching behavior varies by payer and biosimilar availability.

Forecast framing (what actually moves the needle)

• Biosimilar price erosion and uptake curves determine short-to-mid term revenue trajectory.
• Protocol intensity (rituximab monotherapy vs combination, schedule changes) affects units per patient.
• Regulatory and payer restrictions can accelerate or delay substitution at the pharmacy/infusion center level.

---

What is rituximab’s clinical trial landscape in 2024-2026: what is in phase 3 vs phase 2?

Short answer: Recent activity concentrates on: (1) biosimilar development and extrapolation across indications, (2) optimization of rituximab-based combinations in NHL/CLL, and (3) biomarker-led subpopulation enrichment to improve response rates or reduce toxicity.

Trial types to track now

• Biosimilar comparative trials: PK/PD, immunogenicity, and clinical equivalence with potential indication extrapolation packages.
• Combination trials: Rituximab paired with novel agents (checkpoint inhibitors, BTK inhibitors, BCL2 inhibitors, or other targeted therapies depending on tumor context).
• Schedule and regimen optimization: Dosing interval changes, reduced-intensity strategies, and retreatment paradigms.
• Biomarker-driven studies: CD20 density, Fc receptor polymorphisms, baseline immunoglobulin levels, and MRD-linked endpoints for hematologic malignancies.

Endpoint pattern shift

• Shift toward response durability and MRD-linked outcomes in CLL and indolent NHL studies.
• Safety de-risking becomes more prominent in comparative or combination trials, with infusion reactions and infections monitored as primary discriminators.

(Note: A complete, fully accurate “by-phase” and “by-trial-number” update requires a live registry pull by drug name and synonyms. No such registry dataset is included in the provided context.)

---

Which rituximab biosimilars are most likely to capture share and why?

Short answer: Biosimilar share capture depends on (1) payer adoption and tender frameworks, (2) physician switching comfort driven by interchangeability perception, and (3) evidence packages that support extrapolation to key indications.

Biosimilar adoption variables

• Tender and formulary policies: Often the primary determinant of uptake speed.
• Geography-specific interchangeability rules: Affect substitution at pharmacy level versus infusion center level.
• Clinical comfort with substitution: Influences oncology infusion protocols and practice patterns.
• Immunogenicity profiles: Impact clinician decisions in prior responders or treatment-sensitive subgroups.

Risk to originator revenues

• Multiple competing biosimilars in the same tender region intensify price pressure.
• Loss of preferred status accelerates unit erosion even if clinical demand stays stable.

---

What patents protect rituximab and when do key exclusivity dates fall?

Short answer: The originator’s core protection has largely aged out by now across many jurisdictions, and the current risk profile is dominated by:

• remaining secondary patents (formulations, manufacturing, process, dosing/regimen claims, and method-of-use claims); and
• biosimilar regulatory pathways and any remaining litigation or exclusivity blocks in specific countries.

Patent estate structure to map in litigation

• Composition and antigen binding claims: Historically strongest but generally matured.
• Formulation and concentration: Liquid vs lyophilized formulation claims and stabilizer systems, where still active in some jurisdictions.
• Manufacturing/process patents: Cell line/process steps, purification, and viral inactivation claims that can delay “true” process-equivalent replication.
• Method-of-use claims: Dosing schedules and treatment combinations can create narrower but still relevant barriers.

(Note: A fully accurate patent list with numbers and expiration dates requires Orange Book and jurisdictional patent register data not present in the prompt.)

---

What is the Orange Book status of rituximab in the US?

Short answer: Rituximab is a biologic and is not an NDA product; it is therefore not listed in the classic “Orange Book drug patents” framework the same way small molecules are. US biologics follow the Biologics Price Competition and Innovation Act (BPCIA) pathway, and exclusivity/patent status is typically assessed via biologics patent listings and biosimilar regulatory records rather than the small-molecule Orange Book format.

(Note: A precise “Orange Book-like” listing for the relevant rituximab biologics is not possible without the specific BLA holder record and the USPTO/biologics patent list dataset.)

---

Which companies are challenging rituximab with biosimilars and where have they won?

Short answer: Multiple biosimilar developers have challenged or marketed rituximab biosimilars in the major markets over time. The winners in each jurisdiction are those that secured formulation approvals, overcame patent/injunction friction where applicable, and then won payer placement through tendering.

What to evaluate in each market

• Regulatory approval date and extrapolated indication scope.
• Initial launch product and whether it carries additional interchangeability or substitution acceptance.
• Settlement or litigation outcomes that remove remaining barriers.

(Note: A company-by-company “which filed where and what happened” requires a live dossier of biosimilar approvals, patent litigation dockets, and settlements.)

---

What patent litigation affects rituximab biosimilar launches?

Short answer: Litigation typically clusters around:

• patent lists tied to the originator’s biologic product and manufacturing,
• method-of-use or formulation patents,
• injunction and stay outcomes that determine market entry timing.

Common litigation outcomes to model

• Early settlement: Allows launch at a defined time or with carve-outs.
• Injunction-driven delay: Extends originator market control in specific geographies.
• Partial invalidation or narrow claim construction: Allows launch with design-around or label scope limitations.

(Note: No litigation docket dataset is included in the prompt, so a factual timeline cannot be produced.)

---

How strong is the patent estate for rituximab today?

Short answer: For business planning, the estate strength is best treated as residual and jurisdiction-specific: many broad originator protections matured, leaving smaller pockets of enforceable rights tied to manufacturing, formulations, or narrowly defined use claims in particular countries.

Practical assessment lens

• Where are remaining enforceable patents? Identify jurisdictional pockets rather than assuming uniform global protection.
• Do remaining claims map to the competing biosimilar’s process? If the biosimilar uses different manufacturing steps, process patents can be less relevant.
• What indications remain covered by method-of-use claims? These can delay label expansion even when core disease approvals remain open.

(Note: A scored patent-strength view by jurisdiction and claim type requires patent register and dossier-level mapping.)

---

How does rituximab compare with other anti-CD20 therapies (obinutuzumab, ofatumumab) on market and clinical adoption?

Short answer: Rituximab retains broad guideline positioning and high uptake due to extensive long-term clinical data and payer familiarity. Competing anti-CD20 antibodies shift practice patterns primarily in specific patient subgroups or regimen comparisons where improved endpoints or tolerability profile justifies switching.

Competitive takeaways

• Obinutuzumab tends to compete in settings where efficacy endpoints (including in certain combinations) support preference.
• Ofatumumab historically competes in CLL settings but faces substitution pressure and evolving standards of care.
• Biosimilars reduce net cost for rituximab and can offset comparative advantages of newer anti-CD20 competitors.

---

What generic entry risks exist for rituximab?

Short answer: There is no “generic” for a monoclonal antibody; the relevant entry risk is biosimilar and interchangeability-driven substitution.

Risk model for biosimilar entry

• Regulatory comparability acceptance (clinical and immunogenicity similarity).
• Patent barriers that create launch timing delay in specific jurisdictions.
• Market access friction: tender wins and formulary inclusion.

---

What formulations and dosing regimens of rituximab are protected by patents or label scope restrictions?

Short answer: Historically, formulation and dosing regimen claims have been the most likely secondary patent categories. In practice, biosimilars that match the originator’s approved formulation and administration pattern reduce the risk of label and patent friction.

Key formulation-adjacent protection themes

• Concentration, excipients, stabilizers, and buffer system claims.
• Lyophilized vs liquid presentation claims (where jurisdictionally enforced).
• Infusion protocol or premedication regimens where method-of-use claims exist.

(Note: A factual “which patents protect which formulations” requires a patent-to-specification map not available in the prompt.)

---

What does the FDA regulatory pathway imply for rituximab biosimilars and exclusivity timelines?

Short answer: US biosimilar development is constrained by BPCIA requirements, including the biosimilarity demonstration package and the patent dispute framework that can delay launch. In the absence of remaining enforceable patent blocks, biosimilar entry timing is largely governed by regulatory review timelines and any settlement or injunction outcomes.

Where delays usually occur

• Patent litigation and resulting stays or injunctions.
• Label negotiations or restricted indication expansion pending patent outcomes.
• Manufacturing consistency data and post-approval compliance.

---

Market projection scenario analysis for rituximab (base, bull, bear): what outcomes change revenue fastest?

Short answer: Revenue swings are driven by biosimilar share velocity and average selling price (ASP) decline. Indication growth is usually secondary in the near term.

Base case (typical)

• Continued biosimilar uptake across core geographies.
• Gradual ASP decline as competitive tendering intensifies.
• Stable underlying disease prevalence and guideline use.

Bull case

• Faster-than-expected utilization in additional lines or improved regimen adoption.
• Slower than anticipated price erosion due to limited tender competition or higher switching friction in some markets.

Bear case

• Aggressive tendering with multiple biosimilars driving steep ASP compression.
• Payer restrictions reduce originator positioning and push rapid substitution.

(Note: Numeric projections require specific market size inputs not included in the prompt.)

---

Key Takeaways

• Rituximab’s commercial outlook is dominated by biosimilar substitution dynamics rather than new-originator competition.
• Clinical development activity is concentrated in biosimilar confirmation, combination regimen optimization, and biomarker-driven patient selection.
• Patent risk is treated as jurisdiction-specific residual secondary protections and litigation-driven launch timing, not uniform global exclusivity.
• Market forecast variability hinges on biosimilar uptake speed and tender-driven ASP decline, with indication-level growth a secondary driver.

---

FAQs

1. What are the most common endpoints used in rituximab biosimilar clinical programs?
2. How do biosimilar tender rules in the US, EU, and UK typically affect rituximab substitution timing?
3. Which rituximab indications have the most sensitive switching behavior among oncologists and infusion centers?
4. What manufacturing changes are most likely to trigger comparability or immunogenicity concerns for rituximab biosimilars?
5. How do rituximab-based regimens compare with newer anti-CD20 and combination standards in DLBCL and FL?

---

References

1. BPCIA framework and biosimilar approval concepts (FDA guidance and regulatory materials).
2. Public FDA/EMA biosimilar development and interchangeability-related guidance.
3. Standard-of-care literature for anti-CD20 therapy in NHL and CLL (major guideline bodies).